Escitalopram for depression, anxiety, or impulse control disorder in Parkinson's disease

Phase 3, open-label, single-arm trial of escitalopram in major depressive disorder (MDD), anxiety disorder and impulse control disorder (ICD), sponsored by Lundbeck. Primary endpoints: Change from baseline in Hamilton Depression Rating Scale, Change from baseline in Hamilton Anxiety Rating Scale and 2 more. Started Jul 2008; status: completed.